ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis
USA - NASDAQ:ORGO - US68621F1021 - Common Stock
5.63 USD
+1.74 (+44.73%)
5.75 USD
+0.12 (+2.13%)
Overall ORGO gets a fundamental rating of 4 out of 10. We evaluated ORGO against 531 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
ORGO had a negative operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -3.38%, ORGO belongs to the best of the industry, outperforming 87.87% of the companies in the same industry.
Looking at the Return On Equity, with a value of -4.32%, ORGO belongs to the top of the industry, outperforming 89.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.38% | ||
| ROE | -4.32% | ||
| ROIC | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ORGO's Operating Margin has declined in the last couple of years.
The Gross Margin of ORGO (74.58%) is better than 83.21% of its industry peers.
ORGO's Gross Margin has been stable in the last couple of years.
ORGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.58% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ORGO has less shares outstanding
Compared to 5 years ago, ORGO has more shares outstanding
Compared to 1 year ago, ORGO has an improved debt to assets ratio.
2.2 Solvency
ORGO has an Altman-Z score of 5.41. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
ORGO has a better Altman-Z score (5.41) than 76.31% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ORGO is not too dependend on debt financing.
ORGO has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ORGO outperforms 50.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.41 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
A Current Ratio of 3.95 indicates that ORGO has no problem at all paying its short term obligations.
With a Current ratio value of 3.95, ORGO perfoms like the industry average, outperforming 45.90% of the companies in the same industry.
A Quick Ratio of 3.45 indicates that ORGO has no problem at all paying its short term obligations.
ORGO has a Quick ratio (3.45) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.95 | ||
| Quick Ratio | 3.45 |
3. Growth
3.1 Past
The earnings per share for ORGO have decreased strongly by -90.91% in the last year.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
ORGO shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.29%.
The Revenue has been growing by 13.05% on average over the past years. This is quite good.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)11.29%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
3.2 Future
Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 46.59% on average per year.
Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 12.92% on average per year.
EPS Next Y-136%
EPS Next 2Y36.38%
EPS Next 3Y46.59%
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 563.00, the valuation of ORGO can be described as expensive.
89.37% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
ORGO is valuated expensively when we compare the Price/Earnings ratio to 26.06, which is the current average of the S&P500 Index.
ORGO is valuated rather expensively with a Price/Forward Earnings ratio of 17.81.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaper than 94.03% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 32.73. ORGO is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 563 | ||
| Fwd PE | 17.81 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaper than 89.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 202.93 |
4.3 Compensation for Growth
ORGO's earnings are expected to grow with 46.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3Y46.59%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.63
+1.74 (+44.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.08%
Inst Owner Change2.04%
Ins Owners31.49%
Ins Owner Change0.22%
Market Cap714.22M
Revenue(TTM)482.04M
Net Income(TTM)-15.59M
Analysts85
Price Target8.16 (44.94%)
Short Float %16.47%
Short Ratio16.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73%
Min EPS beat(2)-73%
Max EPS beat(2)-73%
EPS beat(4)2
Avg EPS beat(4)278.21%
Min EPS beat(4)-73%
Max EPS beat(4)688.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.3%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)-4.23%
Revenue beat(4)2
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.38%
Revenue beat(12)5
Avg Revenue beat(12)0.07%
Revenue beat(16)6
Avg Revenue beat(16)-0.09%
PT rev (1m)0%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.77%
EPS NY rev (1m)0%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 563 | ||
| Fwd PE | 17.81 | ||
| P/S | 1.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.98 | ||
| P/tB | 2.22 | ||
| EV/EBITDA | 202.93 |
EPS(TTM)0.01
EY0.18%
EPS(NY)0.32
Fwd EY5.62%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS3.39
BVpS2.85
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.38% | ||
| ROE | -4.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.58% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score3
Asset Turnover0.93
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 74.48% | ||
| Cap/Sales | 3.07% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.95 | ||
| Quick Ratio | 3.45 | ||
| Altman-Z | 5.41 |
F-Score3
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-136%
EPS Next 2Y36.38%
EPS Next 3Y46.59%
EPS Next 5YN/A
Revenue 1Y (TTM)11.29%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
EBIT growth 1Y-221.35%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year410.89%
EBIT Next 3Y109.75%
EBIT Next 5YN/A
FCF growth 1Y-140.26%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-297.24%
OCF growth 3Y-38.8%
OCF growth 5YN/A
ORGANOGENESIS HOLDINGS INC / ORGO FAQ
Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?
ChartMill assigns a fundamental rating of 4 / 10 to ORGO.
What is the valuation status for ORGO stock?
ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.
How profitable is ORGANOGENESIS HOLDINGS INC (ORGO) stock?
ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 4 / 10.
What is the valuation of ORGANOGENESIS HOLDINGS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ORGANOGENESIS HOLDINGS INC (ORGO) is 563 and the Price/Book (PB) ratio is 1.98.
Can you provide the expected EPS growth for ORGO stock?
The Earnings per Share (EPS) of ORGANOGENESIS HOLDINGS INC (ORGO) is expected to decline by -136% in the next year.